Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Cost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsReceivables - NetReceivables - OtherShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Corcept Therapeutics (CORT) Shares Issued (2016 - 2026)

Corcept Therapeutics (CORT) has disclosed Shares Issued for 14 consecutive years, with $2.5 million as the latest value for Q1 2026.

  • For Q1 2026, Shares Issued rose 45.8% year-over-year to $2.5 million; the TTM value through Mar 2026 reached $16.7 million, up 166.27%, while the annual FY2025 figure was $15.9 million, 190.69% up from the prior year.
  • Shares Issued hit $2.5 million in Q1 2026 for Corcept Therapeutics, down from $2.9 million in the prior quarter.
  • Across five years, Shares Issued topped out at $8.0 million in Q3 2025 and bottomed at -$205000.0 in Q4 2022.
  • Average Shares Issued over 5 years is $1.9 million, with a median of $1.6 million recorded in 2022.
  • Year-over-year, Shares Issued crashed 106.73% in 2022 and then skyrocketed 526.83% in 2023.
  • Corcept Therapeutics' Shares Issued stood at -$205000.0 in 2022, then surged by 526.83% to $875000.0 in 2023, then surged by 75.09% to $1.5 million in 2024, then surged by 86.75% to $2.9 million in 2025, then dropped by 11.32% to $2.5 million in 2026.
  • According to Business Quant data, Shares Issued over the past three periods came in at $2.5 million, $2.9 million, and $8.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.